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Aims: Hypersecretion of glucagon and reduced insulin secretion both contribute to hyperglycemia in type 2
diabetes (T2DM). However, the relative contributions of impaired glucagon and insulin secretions in glucose
excursions at the various stages of T2DM development remain to be determined.
Methods: The responses of glucagon and insulin as well as those of glucose-dependent insulinotropic
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) were examined before and after ingestion of glucose or
mixed meal in Japanese subjects with normal or impaired glucose tolerance (NGT and IGT) and in non-obese,
untreated T2DM of short duration.
Results: In OGTT, T2DM showed a rise in glucagon at 0–30 min, unlike NGT and IGT, along with reduced insulin.
In MTT, all three groups showed a rise in glucagon at 0–30 min, with that in T2DM being highest, while T2DM
showed a signiﬁcant reduction in insulin. Linear regression analyses revealed that glucose area under the curve
(AUC)0–120 min was associated with glucagon-AUC0–30 min and insulin-AUC0–30 min in both OGTT and MTT. Total
and biologically intact GIP and GLP-1 levels were similar among the three groups.
Conclusions: Disordered early phase insulin and glucagon secretions but not incretin secretion are involved in
hyperglycemia after ingestion of nutrients in T2DM of even a short duration.
© 2015 The authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Postprandial glucose homeostasis is controlled by the two counter-
acting hormones glucagon and insulin. Unger ﬁrst proposed a two
hormone abnormality theory of diabetes pathophysiology in whichnology, andMetabolism, Kansai
0003, Japan. Tel.: +81 6 6458
be),
koneMunicipal Hospital, 1882
arch Institute Kitano Hospital,
nc. This is an open access article unreduced secretion of glucose-lowering insulin and enhanced secretion
of glucose-elevating glucagon both play key roles in postprandial
hyperglycemia in diabetes (Unger & Cherrington, 2012). Many
investigators have noted that glucagon secretion is enhanced in type 2
diabetes (T2DM), and might thereby aggravate postprandial glucose
levels already raised by reduced insulin secretion (Reaven, Chen, Golay,
et al., 1987; Seino, Goto, Kurahachi, et al., 1977). The contributions of
each of these defects to glucose excursion after ingestion of glucose or
mixed meal during the progression of the disease remain to be
determined. In addition, studies of insulin secretion have found
impairment of insulin secretion to be an early manifestation (Haffner,
Miettinen,Gaskill, et al., 1996;Weyer, Bogardus,Mott, et al., 1999), but it
remains unknown when impaired glucagon secretory defects appear
during T2DM development.der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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secretion remain unclear, even though the mechanisms involved in
regulating insulin secretion are rapidly being elucidated (Prentki,
Matschinsky, & Madiraju, 2013; Seino, Shibasaki, & Minami, 2011). It
has been postulated that glucagon secretion by glucose relies on
several different factors: 1) neural sensing of glucose and subsequent
regulation ofα cells, 2) indirectly by sensingglucose fromneighboringβ
cells, which secrete insulin as well as γ-aminobutyric acid, zinc and
glutamate, and δ cells, which secrete somatostatin, and 3) intrinsically
by glucose sensing of α cells by mechanisms still under investigation
(Kawamori, Welters, & Kulkarni, 2010; Marroqui, Alonso-Magdalena,
Merino, et al., 2014). Some amino acids (e.g., arginine, alanine, and
glutamine) are potent stimulators of glucagon secretion, accounting for
most glucagon release after protein intake. Chronic elevation of fatty
acids, often seen in T2DM,may also enhance glucagon secretion, but by
unknown mechanisms.
Glucagon-like peptide-1 (GLP-1) and glucose-dependent insuli-
notropic peptide (GIP) are incretins secreted from the gut in response
to ingestion of various nutrients, and stimulate insulin secretion from
pancreatic β cells glucose-dependently (Drucker, 2013; Holst, 2007;
Seino & Yabe, 2013). Interestingly, the incretins exert opposing effects
on glucagon secretion: GLP-1 suppresses glucagon and GIP enhances
glucagon secretion (Christensen, Calanna, Sparre-Ulrich, et al., 2014;
Christensen, Vedtofte, Holst, et al., 2011; Drucker, 2013; Holst, 2007;
Mentis, Vardarli, Kothe, et al., 2011; Seino & Yabe, 2013; Taminato,
Seino, Goto, et al., 1977). Accordingly, impaired secretion and/or
action of GLP-1 or GIP could contribute to the development of T2DM.
In the current study, wemeasured the levels of insulin and glucagon
and those of the incretins in Japanese subjects with normal glucose
tolerance (NGT), relatively mild IGT, and untreated T2DM to clarify
changes in glucagon secretion during the course of T2DMdevelopment.
2. Materials and methods
The protocol (UMIN registration number: UMIN000014575) was
approved by the ethics committee of each participating institute, and
written informed consent was obtained from all participants. The study
was conducted according to the principles expressed in the Declaration
of Helsinki.
Subjects of NGT, IGT and T2DM, with body mass index (BMI) less
than 27.0 kg/m2 and age between 20 and 65 years, were purposely
recruited in order to evaluate changes in secretions of glucagon and
insulin during the development of non-obese T2DM,which is typically
seen among East Asians (Moller, Pedersen, Tanaka, et al., 2014; Ntuk,
Gill, Mackay, et al., 2014). At screening, subjects with type 1 diabetes,
gastrointestinal tract disease, cardiac disease, pancreatic disease, liver
disease, renal disease, alcohol or drug abuse, anti-diabetic medication,
diabetogenic medication or malignancy, or pregnancy were excluded.
T2DM with HbA1c 7.9% or above were excluded from the study.
Non-diabetic subjects with FPG 110 mg/dL or above were excluded
from the study. Of 145 total subjects screened, 18, 17 and 4 subjects
were excluded due to the inclusion criteria for BMI, age or both. One
T2DM was excluded for HbA1c above 7.9%, and four non-diabetic
subjects were excluded for FPG above 110 mg/dL. Diagnosis of NGT,
IGT and T2DM was according to the criteria of the Japanese Diabetes
Society (Seino, Nanjo, Tajima, et al., 2010).
Participants were subjected to both oral glucose and meal
tolerance tests (OGTT and MTT) in the morning after an overnight
fast on two separate days, as described previously (Yabe, Kuroe, Lee,
et al., 2010). Brieﬂy, 75 grams of glucose or a Japanese standard meal
(480 kcal, carbohydrate: protein: fat = 2.8:1:1) was ingested within
5 and 10 min, respectively. Blood samples were withdrawn from a
cubital vein of the subjects directly into evacuated sample tubes
containing relevant preservatives [e.g., ethylenediaminetetraaceta-
te-2Na and aprotinin-containing tubes (catalogue no. NP-EA0305;
Terumo, Tokyo, Japan) for glucagon; and BD P700 tubes (catalogueno. 366473; BD, Franklin Lakes, NJ, USA) for GLP-1 and GIP)] using
Venoject II Multisample Luer Adaptor S and tube holder D (catalogue
nos. XX-MN2000S and XX-VP010HD; Terumo, Tokyo, Japan). These
tubes were kept on ice until centrifugation. Separated plasma samples
were frozen and kept at −70 °C until further analysis.
2.1. Laboratory determinations
Glucagon was measured using Glucagon kit “Daiichi-II” (TFB Co.
Ltd., Tokyo, Japan; detection limit b30 ng/mL; intra- and interassay
CV 5.0–10.0%). This glucagon assay utilizes antiserum OAL123,
previously reported speciﬁc for pancreatic glucagon and showing
limited cross-reactivity with gut glucagon-like immunoreactivity
(Nishino, Kodaira, Shin, et al., 1981). Insulin was measured using
lumipulse presto insulin (Fujirebio Inc., Tokyo, Japan; detection limit
b0.1 ng/mL; intra- and interassay CV b5.0%; human proinsulin
cross-reaction 0% with 2500 pg/mL of proinsulin). Because GLP-1
and GIP undergo rapid degradation by dipeptidyl peptidase-4 (DPP-4)
and soon lose their biological effects, both intact and total GLP-1 and
GIP weremeasured as described previously (Yabe et al., 2010). Brieﬂy,
aliquots of plasma were extracted with ethanol at the ﬁnal
concentration of 70% (vol/vol), and dried extracts were reconstituted
in the original volume prior to measuring incretins. Total GLP-1 was
measured using antiserum 89390 speciﬁc for the amidated COOH-
terminus of GLP-1 and detection of GLP-1 (7–36) amide and GLP-1
(9–36) amide (detection limit: b1 pM). Intact GLP-1 was measured
using a two-site sandwich enzyme-linked immunesorbent assay,
which detects GLP-1 (7–36) amide and GLP-1 (7–37) but not the
NH2-terminally truncated metabolites, using two monoclonal anti-
bodies, the near C-terminally directed GLP1F5 as a catching antibody
and the strictly N-terminally directedMab26.1 as a detecting antibody
(detection limit: b0.5 pM). This assay has 100% cross-reactivity with
GLP-1 (7–36) amide and 88% with GLP-1 (7–37), but b0.1% with
either GLP-1 (9–36) amide or GLP-1 (9–37). Total GIP was measured
using the COOH-terminally directed antiserum R65, reacting with
intact GIP and GIP (3–42) but not with 8-kDa GIP, the chemical nature
and relation to GIP secretion of which is uncertain (detection limit, 2
pM). Intact, biologically active GIP was measured using antiserum
98171, speciﬁc for the intact GIP, and cross-reacting b0.1% with GIP
(3–42) (detection limit: 5 pM). The intra- and inter-assay variations
for intact GIP, total GIP and total GLP-1were b15% and for intact GLP-1
was b5%. Other laboratory measurements including HbA1c, plasma
glucose (PG) and serum lipids were measured by standard assays.
2.2. Calculations and statistical analyses
Results are reported as mean ± standard error of the mean unless
otherwise stated. Area under the curve (AUC) of eachmeasurement was
calculated according to the trapezoidal rule. All statistical calculations,
including linear regression analyses, were performed using IBM SPSS for
Windows ver. 22 (SAS Institute Inc., Berkeley CA). Repeated measures
were analyzed bymixed effectsmodel. Values at single time points were
compared by Wilcoxon rank sum test. A p value b0.05 was taken to
indicate signiﬁcant differences. Insulin resistance and β cell functionwas
calculated according to the homeostasis model assessment (HOMA)
model (Matthews, Hosker, Rudenski, et al., 1985). II and glucagonostatic
index (GI)were calculated as follows: II,Δinsulin30–0 min/ΔPG30–0 min; GI,
Σ(Δglucagon10–0 min/ΔPG10–0 min + Δglucagon20–0 min/ΔPG20–0
min + Δglucagon30–0 min/ΔPG30–0 min + Δglucagon60–0 min/ΔPG60–0
min+ Δglucagon120–0 min/ΔPG120–0 min) (Seino, Ikeda, Kurahachi, et al.,
1978). Secretory units of islets in transplantation (SUIT) index and
C-peptide index (CPI) were calculated as follows: SUIT index,
250 × [fasting C-peptide (nmol/L)]/([fasting plasma glucose (mmol/
L)]−3.43) (Yamada, Fukuda, Fujimoto, et al., 2006); CPI, [fasting
C-peptide (ng/mL)]/[fasting plasma glucose (mg/dL)] × 100 (Iwata,
Maeda, Kamura, et al., 2012).
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The changes in the secretions of glucagon and insulin during the
development of non-obese T2DMwere evaluated by OGTT andMTT in
non-obese individuals with T2DM, IGT or NGT (Table 1). Non-obese
and untreated T2DM subjects with short duration of the disease were
purposely recruited in this study, so the average disease duration is
relatively short, and the mean BMI is less in comparison with the
other ethnic groups previously reported (Ntuk et al., 2014). Fasting
PG was slightly but elevated in T2DM compared to NGT [NGT versus
(vs.) T2DM, p b 0.05] and IGT (IGT vs. T2DM, p b 0.05) (Table 1 and
Fig. 1A). Despite the small elevation in fasting glucose, there was
robust elevation in PG in T2DM after ingestion of glucose (NGT vs.
T2DM, p b 0.05; IGT vs. T2DM, p b 0.05) and, to a lesser degree,
ingestion of mixed meal (NGT vs. T2DM, p b 0.05; IGT vs. T2DM,
p b 0.05). PG after ingestion of glucose or mixed meal was mild but
elevated in IGT (NGT vs. IGT, p b 0.05).
3.1. Insulin and glucagon
Fasting insulin was elevated in T2DM compared to NGT (NGT vs.
T2DM, p b 0.05) (Fig. 1). In contrast, the indices related to β cell
function, HOMA- β and SUIT, were reduced in T2DM (NGT vs. T2DM,
p b 0.05) (Table 1). Importantly, insulin in the early phase after
ingestion of glucose or mixed meal (insulin-AUC0–30 min and II) was
reduced in T2DM compared to NGT (NGT vs. T2DM, p b 0.05) (Fig. 1A
and B). In IGT, insulin in the early phase after ingestion of glucose, but
not of mixed meal, showed mild impairment compared to NGT; II and
insulin-AUC0–30 min were numerically less in IGT compared to NGT
[NGT vs. IGT, not signiﬁcant (ns)]. Insulin was higher in IGT and T2DM
than in NGT at 90 min and 120 min after ingestion of glucose or
mixed meal (NGT vs. IGT, p b 0.05; NGT vs. T2DM, p b 0.05) (Fig. 1A),
suggesting that insulin resistance may already occur in IGT. C-peptide
levels showed similar proﬁles to those of insulin (Fig. S1).
Fasting glucagon was higher in T2DM compared to NGT and IGT
(NGT vs. T2DM, ns; IGT vs. T2DM, ns) (Fig. 1A). Ingestion of glucose
suppressed glucagon in NGT and IGT, while glucagon was increased in
T2DM, the so-called paradoxical rise of glucagon after ingestion of
glucose in T2DM (Unger & Cherrington, 2012). GI, which estimates
glucagon being suppressed by glucose, was lower in IGT and T2DM
than in NGT (NGT vs. IGT, ns; NGT vs. T2DM, p b 0.05) in OGTT
(Fig. 1B). Ingestion of mixed meal signiﬁcantly increased glucagon in
all groups, but glucagon remained signiﬁcantly higher in T2DM (NGTTable 1
Characteristics of subjects with normal glucose tolerance, impaired glucose tolerance and t
NGT
n (male/female) 54 (31/19)
Age (year) 41.0 ± 8.6
BMI (kg/m2) 21.3 ± 2.4
Duration of diabetes (year) –
Fasting plasma glucose (mg/dL) 89.0 ± 7
2 hr plasma glucose after OGTT (mg/dL) 114.8 ± 12.8
HbA1c (%, mmol/mol) 5.4 ± 0.2, 36 ± 6
HOMA-IR 1.17 ± 0.49
HOMA-ß 78.7 ± 46.2
CPI 1.6 ± 0.48
SUIT 86.7 ± 37.9
Systolic blood pressure (mmHg) 118.5 ± 14.3
Diastolic blood pressure (mmHg) 72.9 ± 9
Total cholesterol (mg/dL) 186.4 ± 36.4
HDL cholesterol (mg/dL) 64.4 ± 15.8
Triglyceride (mg/dL) 80.5 ± 64.4
Each value indicates the mean ± standard deviation. * and # represent statistical differen
glucose tolerance; IGT, impaired glucose tolerance; T2DM, type 2 diabetes; BMI, bodymass in
HDL, high density lipoprotein; OGTT, oral tolerance test; SUIT, secretory unit of islet in tranvs. T2DM, p b 0.05; IGT vs. T2DM, p b 0.05). GI was similar among all
three groups in MTT (Fig. 1B), suggesting that responsiveness of
glucagon secretion to nutrients other than glucosemay not be affected
in T2DM. Consistentwith the changes in insulin and glucagon, themolar
ratio of insulin to glucagonwas affected in T2DM in the early phase after
ingestion of glucose or mixed meal (insulin/glucagon-AUC0–30 min)
(NGT vs. T2DM, p b 0.05) (Fig. 1A). Although the speciﬁcity and
sensitivity of glucagon immunoassays is debated (Bak, Albrechtsen,
Pedersen, et al., 2014), the current results on glucagon in T2DM during
OGTT and MTT are consistent with previous observations.
Association of insulin and glucagon secretionwith glucose excursion
after ingestion of glucose or mixed meal (glucose-AUC0–120 min) was
evaluated to quantify the insulin and glucagon secretion in developing
diabetes. II was associated with glucose-AUC0–120 min in both OGTT and
MTT; GI was correlated only in OGTT (Table 2). Insulin-AUC0–30 min and
glucagon-AUC0–30 min and insulin/glucagon-AUC0–30 min showed signif-
icant associations with glucose-AUC0–120 min in both OGTT and MTT
(Table 2 and Fig. 2). Associations of insulin-AUC0–30 min and
glucagon-AUC0–30 min with glucose-AUC0–120 min were similar; associations
insulin/glucagon-AUC0–30 min were more striking than those of
insulin-AUC0–30 min and glucagon-AUC0–30 min. Multiple regression analysis
of glucose-AUC0–120 min, taking into account both insulin-AUC0–30 min and
glucagon-AUC0–30min, revealedalmost equivalent contributionsof impaired
insulin and glucagon secretions in hyperglycemia after ingestion of
glucose or meal (Table S1). These results suggest that the
disordered insulin and glucagon responses in the early phase
contribute to a similar extent to hyperglycemia after ingestion of
glucose or mixed meal.
Among the three glucose tolerance groups, association of II with
glucose-AUC0–120 min was observed in all groups with similar correlation
coefﬁcients during OGTT and MTT, although it did not reach statistical
signiﬁcance in IGT (Table S2). GI showed a signiﬁcant association with
glucose-AUC0–120 min during OGTT only in T2DM. The correlation
coefﬁcient of glucagon-AUC0–30 min with glucose-AUC0–120 min in OGTT
alsowas signiﬁcant only in T2DM;no signiﬁcant associationwasobserved
in any of the three groups during MTT. The changes in insulin secretion
determined by II might well contribute similarly in the different glucose
tolerance groups to post-challenge hyperglycemia during OGTT andMTT.
On the other hand, changes in glucagon secretion, as determined by
glucagon-AUC0–30 min, may contribute to post-challenge hyperglycemia
more in T2DM than in NGT or IGT in OGTT, suggesting the presence of
factors that suppress the glucose-elevating actions of glucagon inNGTand
IGT and/or augment glucagon action in T2DM.ype 2 diabetes.
IGT T2DM
20 (9/11) 28 (25/3)
52.4 ± 9.1* 56.0 ± 6.1*
22.5 ± 2.7 23.5 ± 2.2*
– 3.1 ± 5.0
96.7 ± 15.6* 119.1 ± 20.5*,#
153 ± 39* 240.9 ± 69.1*,#
5.9 ± 0.6, 41 ± 6* 6.5 ± 0.6, 48 ± 6*,#
1.81 ± 1.19 2.85 ± 3.26*
79.1 ± 55.2 60 ± 43.9*
1.95 ± 0.94 1.84 ± 0.76
84.6 ± 42.9 63.5 ± 30.9*
125.6 ± 16.1 127 ± 16.4*
79.3 ± 10.4* 76.7 ± 9.6
195.3 ± 25.8 203 ± 33.1*
62.9 ± 15.1 55.6 ± 13.8
112.2 ± 70 121.5 ± 55.6*
ce versus NGT and IGT, respectively (Wilcoxon rank sum test, p b 0.05). NGT, normal
dex; CPI, C-peptide index; HOMA, homeostatic model assessment; IR, insulin resistance;
splantation.
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Table 2
Associations of glucose excursions after ingestions of glucose or mixed meal with
insulin and glucagon secretion.
OGTT
glucose-
AUC0–120 min
MTT
glucose-
AUC0–120 min
R p R p
Age (years) 0.542 .000 0.557 .000
BMI (kg/m2) 0.295 .003 0.256 .009
HOMA-ß (%) −0.269 .006 −0.28 .004
HOMA-IR 0.378 .000 0.309 .002
SUIT −0.380 .000 −0.35 .000
CPI 0.059 .557 .038 .708
Insulinogenic index −0.496 .000 −0.469 .000
Glucagonostatic index −0.388 .000 .047 .639
Fasting insulin (mU/L) 0.262 .008 0.203 .041
Insulin-AUC0–30 min (mU/L × min) −0.300 .002 −0.21 .034
Insulin-AUC0–120 min (mU/L × min) 0.001 .990 .152 .127
Fasting glucagon (pg/mL) 0.135 .176 .183 .065
Glucagon-AUC0–30 min (pg/mL × min) 0.246 .013 0.234 .018
Glucagon-AUC0–120 min (pg/mL × min) 0.211 .033 0.248 .012
Fasting insulin/glucagon ratio 0.192 .053 .027 .785
Insulin/glucagon ratio-AUC0–30 min (× min) −0.418 .000 −0.418 .000
Insulin/glucagon ratio-AUC0–120 min (× min) −0.160 .108 −0.229 .021
AUC, area under curve; BMI, body mass index; CPI, C-peptide index; HOMA, homeostatic
model assessment; IR, insulin resistance; SUIT, secretory unit of islet in transplantation
p values were calculated by linear regression analysis; R, correlation coefﬁcient.
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As glucose excursion after ingestion of glucose or mixed meal is
associated with insulin and glucagon responses in the early phase
(Fig. 2 and Tables 2 and S1), the incretin levels were examined. Since
numerous GLP-1 immunoassays have become available, evaluation of
the GLP-1 level requires special consideration; recent incorporation
of an extraction step improves speciﬁcity but reduces the value of
intact GLP-1 in circulation (Deacon & Holst, 2009; Yabe, Watanabe,
Sugawara, et al., 2012), and the speciﬁcity and sensitivity of each
assay varies considerably (Bak, Wewer Albrechtsen, Pedersen, et al.,
2014). The well-characterized assays developed by the laboratory of
Holst have been used throughout in this study. Total and intact forms
of GIP and GLP-1 levels were similar before and after ingestion of
glucose or mixed meal among the three groups (Fig. 3A). Consistent
with our previous observation (Yabe et al., 2010), total GLP-1 was
increased after ingestion of glucose but not of mixedmeal. The ratio of
intact and total GLP-1 was much lower than that of GIP (Fig. 3B),
presumably due to more rapid turnover of intact GLP-1 than that of
intact GIP (Deacon & Holst, 2009). Nevertheless, the lack of signiﬁcant
differences in GLP-1 and GIP secretion among individuals with differing
glucose tolerance indicates that there is little involvement of GLP-1 or
GIP secretion in the impaired insulin and glucagon secretions seen in
T2DM. Furthermore, linear regression analyses showed no signiﬁcant
association of the indices related to insulin or glucagon secretions with
fasting or post-challenge incretin levels (Table S3).
4. Discussion
We ﬁnd in this study that disturbed secretion of both insulin and
glucagon in the early phase after ingestion of glucose or mixed meal
plays a similarly important role in post-challenge hyperglycemia in
Japanese (Fig. 2 and Tables 2 and S1). The two hormone abnormality
theory of type 2 diabetes pathogenesis was initially proposed by
Roger Unger more than 40 years ago (Unger, 1976; Unger &
Cherrington, 2012). Many investigators have noticed that glucagon
secretion is indeed enhanced in T2DM, possibly aggravating post-
prandial glucose levels in collaboration with reduced insulin secretion
(Kurahachi, Seino, Ikeda, et al., 1977; Reaven et al., 1987; Seino et al.,
1977; Shah, Vella, Basu, et al., 2000). However, few studies have
investigated the contributions of the impaired insulin and glucagon
secretions in post-challenge hyperglycemia. We show in this study
that impaired secretions of both insulin and glucagon in the early
phase after ingestion of glucose or mixed meal play a similarly
important role in post-challenge hyperglycemia of Japanese T2DM.
Previous studies have demonstrated that secretions of glucagon and
insulin as well as the incretins depend on meal size and composition
in healthy subjects as well as in patients with diabetes (Alsalim,
Omar, Pacini, et al., 2014; Kawai, Murayama, Okuda, et al., 1987;
Rijkelijkhuizen, McQuarrie, Girman, et al., 2010).We used glucose and
mixed meal of ﬁxed size and composition in the current study; it
would be interesting to see if there is any difference when meal size
and composition is altered.
As found in our study and others, glucagon secretion is increased
and is no longer adequately suppressed by glucose in T2DM. The
mechanisms underlying impaired glucagon secretion in T2DM are of
special importance to potential therapeutics for diabetes; however,
the dysregulated secretion of glucagon from pancreatic α cells is still
largely unexplained (Kawamori et al., 2010; Marroqui et al., 2014).Fig. 1. (A) Changes in glucose, glucagon and insulin levels as well as insulin/glucagon molar ratio after ingestion of oral glucose or mixed meal in Japanese subjects with norma
glucose tolerance (NGT), impaired glucose tolerance (IGT), and type 2 diabetes (T2DM). The same subjects received 75-gram oral glucose and meal tolerance tests (OGTT and MTT)
on two separate mornings after overnight fasting. Left, levels of indicated measurements at each time point (blue, NGT; yellow, IGT; and red, T2DM). Right, area-under-the curve
(AUC) for indicatedmeasurements is indicated (blue, NGT; yellow, IGT; and red, T2DM). (B) Insulinogenic index and glucagonostatic indexwere calculated according to themethods
described in Materials andMethods, and indicated (blue, NGT; yellow, IGT; and red, T2DM). Each value represents the mean ± standard error of the mean. Time course curves were
analyzed by mixed effects models including diagnosis, time and the interaction of diagnosis, and p values are indicated. For explanatory analyses, Wilcoxon rank sum test with
Bonferroni correction is performed at single time points. * and # indicate signiﬁcant differences versus NGT and IGT, respectively (Bonferroni adjusted p b 0.05)..We previously reported that near-normalization of glycemia by
insulin or SU does not reverse increased glucagon secretion in
Japanese T2DM (Seino et al., 1978), indicating that glucagon
hypersecretion is not a secondary event in chronic hyperglycemia. It
is known that glucose is the most effective regulator of glucagon
secretion both in hypoglycemic and hyperglycemic conditions, and
that glucose controls glucagon secretion by both direct and indirect
mechanisms (Kawamori et al., 2010; Marroqui et al., 2014). The
indirect mechanism of suppression of glucagon secretion involves the
actions of insulin in pancreatic α cells, suggesting that impaired
insulin secretion and/or actionmay play an important role in glucagon
secretion in T2DM (Kawamori et al., 2010; Marroqui et al., 2014).
Although no association was found between insulin-AUC0–30 min and
glucagon-AUC0–30 min during OGTT in the current study, Ahren
reported that reduced insulin-induced glucagon suppression could
be seen in IGT ofWhitewomen (Ahren& Larsson, 2001),which suggests
impairment of insulin-mediated suppression of glucagon secretion, but
little is knownof possible insulin resistance in pancreaticα cells. Further
investigation is required to clarify the mechanisms underlying the
dysregulated secretion of glucagon in T2DM.
Another remaining question is at which stage of disease progres-
sion impairment of glucagon secretions in response to glucose or
other nutrients begins to occur. Ahren reported that dysregulated
glucagon secretion in response to glucose or the amino acid arginine is
evident in postmenopausal White women several years before
diagnosis of IGT (Ahren, 2009), and no studies have challenged this
observation. In the present investigation, there was no signiﬁcant
impairment of glucagon secretion in response to glucose or meal in
IGT subjects, while impaired glucagon secretion was manifested in
subjects having short duration T2DM. Because our IGT subjects were
recruited as NGT and afterward classiﬁed as IGT according to the OGTT
results, they may well be phenotypically similar to NGT; in fact, IGT in
this study showed no signiﬁcant difference in II and HOMA-IR, unlikel
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Fig. 2. Associations of glucose excursions after ingestions of glucose or mixed meal with insulin and glucagon secretion. Linear regression analyses of glucose area-under-the-curve
(AUC)0–120 min after ingestions of glucose or mixed meal with insulinogenic index, glucagonostatic index, insulin-AUC0–120 min and glucagon-AUC0–120 min as well as insulin/
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Mari, Tura, Pacini, et al., 2008; Raffel, Robbins, Norris, et al., 1996). To
determine at which stage of disease progression impairments of
glucagon secretions begin to occur in T2DMdevelopment, prospective
follow-up studies to investigate glucagon secretion in NGT and IGT
are required.To test possible involvement of the incretin system in the
disordered glucagon secretion, we evaluated the secretion and
metabolism of GIP and GLP-1. The secretion of GIP and GLP-1 did
not differ among the three groups in OGTT or MTT. While earlier
studies reported reduced GLP-1 secretion and enhanced GIP secretion
in T2DM (Drucker, 2013; Holst, 2007; Seino & Yabe, 2013), later
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Fig. 3. (A) Changes in biologically intact and total formsof glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) levels after ingestion of oral glucose or
mixedmeal in Japanese subjectswith normal glucose tolerance (NGT), impairedglucose tolerance (IGT), and type2diabetes (T2DM). The same subjects received75-gramoral glucose and
meal tolerance tests (OGTT andMTT) on two separatemornings after overnight fasting. Left, levels of indicatedmeasurements at each time point (blue, NGT; yellow, IGT; and red, T2DM).
Right, area-under-the curve (AUC) for indicatedmeasurements is indicated (blue, NGT; yellow, IGT; and red, T2DM). Each value represents themean ± standard error of themean. Time
course curveswere analyzed bymixed effectsmodels including diagnosis, time and the interaction of diagnosis, and p values are indicated. (B) AUC0–120 min ratio of biologically intact and
total formsofGLP-1andGIP (blue,NGT; yellow, IGT; and red, T2DM). Eachvalue represents themean ± SEM. For explanatory analyses,Wilcoxon rank sum testwithBonferroni correction
is performed at single time points. * and # indicate signiﬁcant differences versus NGT and IGT, respectively (Bonferroni adjusted p b 0.05).
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2013a, 2013b; Nauck, Vardarli, Deacon, et al., 2010), in accord with
our present study. The ratio between total and intact forms of the
incretins did not differ, indicating similar metabolism among the
three groups and suggesting that DPP-4-dependentmetabolism of GIP
and GLP-1 is not affected by glucose tolerance. Furthermore, we failed
to ﬁnd any relationship, using linear regression analyses, between
fasting or post-challenge levels of total and intact GLP-1 or GIP with
indices related to glucagon secretion (Table S3). It is therefore likely
that changes in secretion and/or metabolism of GLP-1 and GIP do not
by themselves account for the disordered glucagon secretion. It
remains to be determined whether or not the effects of GIP and GLP-1
on glucagon secretion are altered during T2DM development. GLP-1
receptor agonists have been shown to efﬁciently suppress glucagon
secretion as well as enhance insulin secretion (Yabe & Seino, 2014).
Since little is known regarding the long-term effects of GLP-1 receptor
agonists on glucagon and insulin secretion in individualswith prediabetes
or newly diagnosed type 2 diabetes, it is of special interest to evaluate
these secretions with and without GLP-1 receptor agonist treatment.
An impaired incretin effect has been known as one of major
pathophysiological characteristics of T2DM (Bagger, Knop, Lund, et al.,
2011; Knop, Vilsboll, Hojberg, et al., 2007; Nauck, Homberger, Siegel,
et al., 1986), in which attenuated GIP-induced but not GLP-1-induced
insulin secretion is thought to play a role (Vilsboll, Krarup, Madsbad,
et al., 2002). However, recent studies have indicated that GIP-induced
insulin secretion is recovered in well-controlled T2DM (Aulinger,
Bedorf, Kutscherauer, et al., 2014; Hojberg, Vilsboll, Rabol, et al.,
2009). Moreover, Cho et al. demonstrated that incretin effect did not
differ among Korean subjects with different glucose tolerance (Oh,
Kim, Shin, et al., 2014). Although previous studies have shown that
insulin response to intravenous glucose loading is severely impaired
in T2DM, IGT and even prediabetes Davies, Rayman, Grenfell, et al.,
1994, more than two-thirds of the insulin secretion after nutrient
ingestion is derived from incretin effect (Bagger et al., 2011; Knop
et al., 2007; Nauck et al., 1986), suggesting that near-normal actions of
incretinmight alleviate defects in glucose-induced insulin secretion in
IGT and T2DM. Therefore, the near normal insulin secretion during
OGTTandMTT in IGT of the current studymight bedue to normalization
of the incretin effect. Since reports of incretin action on glucose-induced
insulin secretion in IGT are limited, especially in Asians, further
investigations are required.
In conclusion, we ﬁnd that both insulin and glucagon secretion, but
not GIP and GLP-1 secretion, immediately after ingestion of glucose or
mixed meal are signiﬁcantly impaired in subjects having even a short
duration of T2DM; this is not the case in either subjects with NGT or
early-stage IGT. Reduced insulin secretion and enhanced glucagon
secretion, but not incretin secretion, are therefore involved to a
similar degree in post-challenge glucose excursions in these subjects,
suggesting a need for development of treatment strategies that target
both impaired insulin and glucagon secretion.
Funding
This study was funded by Merck, Sharp and Dohme. Costs for
measurement of glucose, insulin, glucagon, GLP-1 andGIPwere covered
by the funder. The funder hadnorole in studydesign, data collectionand
analysis, decision to publish, or preparation of the manuscript.
Conﬂict of interest
D.Y. received consulting and/or speaker fees from Eli Lilly,
Merck, Sharp and Dohme, Sanoﬁ, Novo Nordisk, Boehringer Ingelheim,
TakedaandTaisho pharmaceutical. D.Y. received clinical commissioned/
joint research grants from Boehringer Ingelheim, and Eli Lilly. Y.H.
received speaker's fees from Dainippon Sumitomo Pharma Co.,Ltd.,
Sanoﬁ K.K., Novo Nordisk Pharma Ltd., Eli Lilly Japan K.K., MitsubishiTanabe Pharma Corporation, Merck Sharp & Dohme, Taisho Toyama
Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Novartis Pharmaceu-
ticals Japan, AstraZeneca K.K., and Kowa Company. Ltd. Y.H. also
received research grants from Eli Lilly Japan K.K., Novo Nordisk Pharma
Ltd., Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer
Ingelheim Co., Ltd., Kissei Pharmaceutical Co., Ltd., and Chugai
Pharmaceutical Co., Ltd. K.M. received speaker fees from Takeda. CFD
received lecture/consultancy fees from BMS, Boehringer Ingelheim.
Lilly, Merck, Sharp and Dohme, Novartis, Novo Nordisk. JJH received
lecture/consultancy fees from Astra Zeneca, BMS, Lilly, Merck/MERCK,
SHARPANDDOHME,NovoNordisk, Roche, Takeda. T.H. received clinical
commissioned/joint research grants from Merck, Sharp and Dohme,
Novartis, and Takeda. N.I. served as amedical advisor for Takeda, Taisho
Pharmaceutical, GlaxoSmithKline, Mitsubishi Tanabe Pharma, he
lectured for Merck, Sharp and Dohme, Sanoﬁ, Novartis Pharma,
Dainippon Sumitomo Pharma, Kyowa Kirin, and Mitsubishi Tanabe
Pharma, and received payment for his services. N.I. also received a
clinical commissioned/joint research grant from Merck, Sharp and
Dohme, Eli Lilly Japan, Shiratori Pharmaceutical, Roche Diagnostics,
and the Japan Diabetes Foundation, and also received a scholarship
grant fromMerck, Sharp and Dohme, JT, Nippon Boehringer Ingelheim,
Takeda, Dainippon SumitomoPharma, Astellas Pharma, Daiichi-Sankyo,
and Mitsubishi Tanabe Pharma. K.T. received consulting and/or speaker
fees from Astellas, Boehringer Ingelheim, Sanoﬁ, Novo Nordisk, Sanoﬁ,
NovoNordisk,Merck, Sharp andDohme, Takeda, Kowa, Astellas, Tanabe
Mitsubishi, KakenPharm,AstraZeneca, Daiichi-Sankyo, KyowaKirin.K.T.
also received clinical commissioned/joint research grants from
Boehringer Ingelheim, Novo Nordisk, Merck, Sharp and Dohme, Takeda,
Ono Pharm, Eli Lilly, Teijin, Sanoﬁ. Y.S. recieved consulting and/or
speaker fees from Eli Lilly, Sanoﬁ, Novo Nordisk, Glaxo-Smith-Kline,
Taisho pharmaceutical, Astellas Pharma, BD, Boehringer Ingelheim,
Johnson & Johnson and Takeda. Y.S. received clinical commissioned/
joint researchgrants fromBoehringer Ingelheim, Eli Lilly. A.K., K.W.,M.I.,
N.H., S.Y. and S.L. report no conﬂict of interest.
Contribution statement
DY and YS take responsibility for the contents of the article. DY and
YS designed the research; collected data, and analyzed data andwrote
the manuscript. AK, KW, MI, AH, YH, NH, SY, and SL contributed to
data collection, and discussion. CFD and JJH measured incretins, and
contributed to discussion. KM contributed to statistical analysis, and
discussion. KT, TH, and NI reviewed the manuscript and contributed
to discussion.
Acknowledgement
The authors thank Takeshi Murakami, Takuro Yamaguchi, Shinobu
Shimizu, Eto Hiroaki of Kansai Electric Power Hospital for technical
support. The authors thank Michiko Yamane of Kansai Electric Power
Hospital for secretarial assistance.
Appendix. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jdiacomp.2014.12.010.
References
Ahren, B. (2009). Beta- and alpha-cell dysfunction in subjects developing impaired
glucose tolerance: Outcome of a 12-year prospective study in postmenopausal
Caucasian women. Diabetes, 58, 726–731.
Ahren, B., & Larsson, H. (2001). Impaired glucose tolerance (IGT) is associated with
reduced insulin-induced suppression of glucagon concentrations. Diabetologia, 44,
1998–2003.
Alsalim, W., Omar, B., Pacini, G., et al. (2014). Incretin and islet hormone responses to
meals of increasing size in healthy subjects. The Journal of Clinical Endocrinology and
Metabolism, http://dx.doi.org/10.1210/jc.2014-2865 (Epub ahead of print).
421D. Yabe et al. / Journal of Diabetes and Its Complications 29 (2015) 413–421Aulinger, B. A., Bedorf, A., Kutscherauer, G., et al. (2014). Deﬁning the role of GLP-1 in
the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1
receptor blockade. Diabetes, 63, 1079–1092.
Bagger, J. I., Knop, F. K., Lund, A., et al. (2011). Impaired regulation of the incretin effect
in patients with type 2 diabetes. The Journal of Clinical Endocrinology and
Metabolism, 96, 737–745.
Bak, M. J., Albrechtsen, N. W., Pedersen, J., et al. (2014). Speciﬁcity and sensitivity of
commercially available assays for glucagon and oxyntomodulin measurement in
humans. European Journal of Endocrinology, 170, 529–538.
Bak, M. J., Wewer Albrechtsen, N. J., Pedersen, J., et al. (2014). Speciﬁcity and sensitivity of
commercially available assays for glucagon-like peptide-1 (GLP-1): Implications for GLP-
1 measurements in clinical studies. Diabetes, Obesity & Metabolism, 16, 1155–1164.
Calanna, S., Christensen, M., Holst, J. J., et al. (2013a). Secretion of glucagon-like
peptide-1 in patients with type 2 diabetes mellitus: Systematic review and meta-
analyses of clinical studies. Diabetologia, 56, 965–972.
Calanna, S., Christensen, M., Holst, J. J., et al. (2013b). Secretion of glucose-dependent
insulinotropic polypeptide in patients with type 2 diabetes: Systematic review and
meta-analysis of clinical studies. Diabetes Care, 36, 3346–3352.
Christensen, M., Calanna, S., Sparre-Ulrich, A. H., et al. (2014). Glucose-dependent
insulinotropic polypeptide augments glucagon responses to hypoglycemia in type
1 diabetes. Diabetes, 64, 72–78.
Christensen, M., Vedtofte, L., Holst, J. J., et al. (2011). Glucose-dependent insulinotropic
polypeptide: A bifunctional glucose-dependent regulator of glucagon and insulin
secretion in humans. Diabetes, 60, 3103–3109.
Davies, M. J., Rayman, G., Grenfell, A., et al. (1994). Loss of the ﬁrst phase insulin
response to intravenous glucose in subjects with persistent impaired glucose
tolerance. Diabetic Medicine, 11, 432–436.
Deacon, C. F., & Holst, J. J. (2009). Immunoassays for the incretin hormones GIP and GLP-
1. Best Practice & Research. Clinical Endocrinology & Metabolism, 23, 425–432.
Drucker, D. J. (2013). Incretin action in the pancreas: Potential promise, possible perils,
and pathological pitfalls. Diabetes, 62, 3316–3323.
Fukushima, M., Suzuki, H., & Seino, Y. (2004). Insulin secretion capacity in the
development from normal glucose tolerance to type 2 diabetes. Diabetes Research
and Clinical Practice, 66S, S37–S44.
Haffner, S. M., Miettinen, H., Gaskill, S. P., et al. (1996). Decreased insulin action and
insulin secretion predict the development of impaired glucose tolerance.
Diabetologia, 39, 1201–1207.
Hojberg, P. V., Vilsboll, T., Rabol, R., et al. (2009). Four weeks of near-normalisation of blood
glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent
insulinotropic polypeptide in patients with type 2 diabetes. Diabetologia, 52, 199–207.
Holst, J. J. (2007). The physiology of glucagon-like peptide 1. Physiological Reviews, 87,
1409–1439.
Iwata, M., Maeda, S., Kamura, Y., et al. (2012). Genetic risk score constructed using 14
susceptibility alleles for type 2 diabetes is associated with the early onset of
diabetes and may predict the future requirement of insulin injections among
Japanese individuals. Diabetes Care, 35, 1763–1770.
Kawai, K., Murayama, Y., Okuda, Y., et al. (1987). Postprandial glucose, insulin and
glucagon responses to meals with different nutrient compositions in non-insulin-
dependent diabetes mellitus. Endocrinologia Japonica, 34, 745–753.
Kawamori, D., Welters, H. J., & Kulkarni, R. N. (2010). Molecular pathways underlying
the pathogenesis of pancreatic alpha-cell dysfunction. Advances in Experimental
Medicine and Biology, 654, 421–445.
Knop, F. K., Vilsboll, T., Hojberg, P. V., et al. (2007). Reduced incretin effect in type 2
diabetes: Cause or consequence of the diabetic state? Diabetes, 56, 1951–1959.
Kurahachi, H., Seino, Y., Ikeda, M., et al. (1977). Insuppressibility of plasma glucagon by
orally or intravenously administered glucose in diabetes mellitus. Endocrinologia
Japonica, 24, 413–419.
Mari, A., Tura, A., Pacini, G., et al. (2008). Relationships between insulin secretion after
intravenous and oral glucose administration in subjects with glucose tolerance
ranging from normal to overt diabetes. Diabetic Medicine, 25, 671–677.
Marroqui, L., Alonso-Magdalena, P., Merino, B., et al. (2014). Nutrient regulation of glucagon
secretion: Involvement in metabolism and diabetes. Nutrition Research Reviews, 1–15.
Matthews, D. R., Hosker, J. P., Rudenski, A. S., et al. (1985). Homeostasis model
assessment: Insulin resistance and beta-cell function from fasting plasma glucose
and insulin concentrations in man. Diabetologia, 28, 412–419.
Mentis, N., Vardarli, I., Kothe, L. D., et al. (2011). GIP does not potentiate the antidiabetic
effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes, 60,
1270–1276.Moller, J. B., Pedersen, M., Tanaka, H., et al. (2014). Body composition is the main
determinant for the difference in type 2 diabetes pathophysiology between
Japanese and Caucasians. Diabetes Care, 37, 796–804.
Nauck, M. A., Homberger, E., Siegel, E. G., et al. (1986). Incretin effects of increasing
glucose loads in man calculated from venous insulin and C-peptide responses. The
Journal of Clinical Endocrinology and Metabolism, 63, 492–498.
Nauck, M. A., Vardarli, I., Deacon, C. F., et al. (2010). Secretion of glucagon-like peptide-1
(GLP-1) in type 2 diabetes: What is up, what is down? Diabetologia, 54, 10–18.
Nishino, T., Kodaira, T., Shin, S., et al. (1981). Glucagon radioimmunoassay with use of
antiserum to glucagon C-terminal fragment. Clinical Chemistry, 27, 1690–1697.
Ntuk, U. E., Gill, J. M.,Mackay, D. F., et al. (2014). Ethnic-speciﬁc obesity cutoffs for diabetes
risk: Cross-sectional study of 490,288 UK Biobank participants. Diabetes Care, 37,
2500–2507.
Oh, T. J., Kim, M. Y., Shin, J. Y., et al. (2014). The incretin effect in Korean subjects with
normal glucose tolerance or type 2 diabetes. Clinical Endocrinology, 80, 221–227.
Prentki, M., Matschinsky, F. M., & Madiraju, S. R. (2013). Metabolic signaling in fuel-
induced insulin secretion. Cell Metabolism, 18, 162–185.
Raffel, L. J., Robbins, D. C., Norris, J. M., et al. (1996). The GENNID Study. A resource for
mapping the genes that cause NIDDM. Diabetes Care, 19, 864–872.
Reaven, G. M., Chen, Y. D., Golay, A., et al. (1987). Documentation of hyperglucagonemia
throughout the day in nonobese and obese patients with noninsulin-dependent
diabetes mellitus. The Journal of Clinical Endocrinology andMetabolism, 64, 106–110.
Rijkelijkhuizen, J. M., McQuarrie, K., Girman, C. J., et al. (2010). Effects of meal size and
composition on incretin, alpha-cell, and beta-cell responses.Metabolism, 59, 502–511.
Seino, Y., Goto, Y., Kurahachi, H., et al. (1977). Alteration of plasma glucagon response to
arginine after treatment in patients with diabetes mellitus, cushing's syndrome and
hypothyroidism. Hormone and Metabolic Research, 9, 28–32.
Seino, Y., Ikeda, M., Kurahachi, H., et al. (1978). Failre of suppress plasma glucagon
concentrations by orally administered glucose in diabetic patients after treatment.
Diabetes, 27, 1145–1150.
Seino, Y., Nanjo, K., Tajima, N., et al. (2010). Report of the Committee on the
Classiﬁcation and Diagnostic Criteria of Diabetes Mellitus. Journal of Diabetes
Investigation, 1, 212–228.
Seino, Y., & Yabe, D. (2013). GIP and GLP-1: Incretin actions beyond pancreas. Journal of
Diabetes Investigation, 4, 108–130.
Seino, S., Shibasaki, T., & Minami, K. (2011). Dynamics of insulin secretion and the
clinical implications for obesity and diabetes. Journal of Clinical Investigation, 121,
2118–2125.
Shah, P., Vella, A., Basu, A., et al. (2000). Lack of suppression of glucagon contributes to
postprandial hyperglycemia in subjects with type 2 diabetes mellitus. The Journal of
Clinical Endocrinology and Metabolism, 85, 4053–4059.
Taminato, T., Seino, Y., Goto, Y., et al. (1977). Synthetic gastric inhibitory polypeptide.
Stimulatory effect on insulin and glucagon secretion in the rat. Diabetes, 26,
480–484.
Unger, R. H. (1976). The Banting Memorial Lecture 1975. Diabetes and the alpha cell.
Diabetes, 25, 136–151.
Unger, R. H., & Cherrington, A. D. (2012). Glucagonocentric restructuring of diabetes: A
pathophysiologic and therapeutic makeover. Journal of Clinical Investigation, 122,
4–12.
Vilsboll, T., Krarup, T., Madsbad, S., et al. (2002). Defective ampliﬁcation of the late
phase insulin response to glucose by GIP in obese type II diabetic patients.
Diabetologia, 45, 1111–1119.
Weyer, C., Bogardus, C., Mott, D. M., et al. (1999). The natural history of insulin secretory
dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus.
Journal of Clinical Investigation, 104, 787–794.
Yabe, D., Kuroe, A., Lee, S., et al. (2010). Little enhancement of meal-induced GLP-1
secretion in Japanese: Comparison of type 2 diabetes and healthy controls. Journal
of Diabetes Investigation, 1, 56–59.
Yabe, D., & Seino, Y. (2014). Deﬁning the role of GLP-1 receptor agonists for
individualized treatment of type 2 diabetes. Expert Review of Endocrinology and
Metabolism, 9, 659–670.
Yabe, D., Watanabe, K., Sugawara, K., et al. (2012). Comparison of incretin
immunoassays with or without plasma extraction: Incretin secretion in Japanese
patients with type 2 diabetes. Journal of Diabetes Investigation, 3, 70–79.
Yamada, Y., Fukuda, K., Fujimoto, S., et al. (2006). SUIT, secretory units of islets in
transplantation: An index for therapeutic management of islet transplanted
patients and its application to type 2 diabetes. Diabetes Research and Clinical
Practice, 74, 222–226.
